0000950170-24-016688.txt : 20240216
0000950170-24-016688.hdr.sgml : 20240216
20240216211549
ACCESSION NUMBER: 0000950170-24-016688
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240214
FILED AS OF DATE: 20240216
DATE AS OF CHANGE: 20240216
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ege David S.
CENTRAL INDEX KEY: 0001829360
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37465
FILM NUMBER: 24650389
MAIL ADDRESS:
STREET 1: C/O SERES THERAPEUTICS, INC.
STREET 2: 200 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Seres Therapeutics, Inc.
CENTRAL INDEX KEY: 0001609809
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 274326290
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617 945 9626
MAIL ADDRESS:
STREET 1: 200 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: Seres Health, Inc.
DATE OF NAME CHANGE: 20140603
4
1
ownership.xml
4
X0508
4
2024-02-14
0001609809
Seres Therapeutics, Inc.
MCRB
0001829360
Ege David S.
C/O SERES THERAPEUTICS, INC.
101 CAMBRIDGE PARK DRIVE
CAMBRIDGE
MA
02140
false
true
false
false
See Remarks
true
Common Stock
2024-02-15
4
M
false
11875
A
78866
D
Common Stock
2024-02-16
4
S
false
5010
1.08
D
73856
D
Stock Option (Right to Buy)
1.10
2024-02-14
4
A
false
187500
0
A
2034-02-13
Common Stock
187500
187500
D
Stock Option (Right to Buy)
1.10
2024-02-14
4
A
false
287905
0.00
A
2034-02-13
Common Stock
287905
287905
D
Restricted Stock Units
2024-02-14
4
A
false
31250
0.00
A
Common Stock
31250
31250
D
Restricted Stock Units
2024-02-15
4
M
false
11875
0.00
D
Common Stock
11875
35625
D
Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
The price reported in column 4 is a weighted average of the price. These shares were sold in multiple transactions at prices ranging from $1.08 to $1.115, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The option will vest as to 25% of the shares on February 14, 2025. The remainder of the shares will vest in 12 equal quarterly installments thereafter.
The option will vest, if at all, in two substantially equal installments upon achievement of a 30-day trailing average public market closing price per share of the Issuer's common stock greater than or equal to $3.00 and $5.00, respectively.
The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
Executive Vice President and Chief Technology Officer
/s/ Thomas J. DesRosier, attorney-in-fact for David S. Ege
2024-02-16